DOCSLIB.ORG

Media Release

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Media Release Media Release Review of S&P BSE indices Index Committee of S&P BSE Indices has decided to revise the composition of S&P BSE indices as detailed below, w. e. f. June 24, 2013: 1. S&P BSE 200 Index: Exclusions: Inclusions: Code Name Code Name FFF NEYVELI LIGNITE 513683 534816 BHARTI INFRATEL LIMITED CORPORATION LTD. 0.15 531500 RAJESH EXPORTS LTD. 531162 EMAMI LTD 0.30 500840 EIH LTD 533398 MUTHOOT FINANCE LIMITED 0.20 GUJARAT FLUOROCHEMICALS 500173 505200 EICHER MOTORS LTD. LTD. 0.45 532778 LANCO INFRATECH LTD. 532209 JAMMU AND KASHMIR BANK LTD. 0.50 CHAMBAL FERTILISERS & 500085 509480 BERGER PAINTS INDIA LTD CHEMICALS LTD 0.25 532524 PTC INDIA LTD 500034 BAJAJ FINANCE LIMITED 0.35 532670 SHREE RENUKA SUGARS LTD. 500260 MADRAS CEMENTS LTD., 0.55 502742 SINTEX INDUSTRIES LTD 532800 TV18 BROADCAST LTD. 0.45 532391 OPTO CIRCUITS (INDIA) LTD. 500008 AMARA RAJA BATTERIES LTD 0.50 532693 PUNJ LLOYD LTD 532218 SOUTH INDIAN BANK LTD. 1.00 530773 IVRCL LTD 532652 KARNATAKA BANK LTD. 1.00 2. S&P BSE 500 Index: Exclusions: Inclusions: Code Name Code Name FFF 531900 CCL INTERNATIONAL LTD 531465 NOUVEAU GLOBAL VENTURES 0.65 LIMITED 531426 TAMILNADU NEWSPRINT & 526045 LUMINAIRE TECHNOLOGIES LTD 0.75 PAPERS 523838 SIMPLEX INFRASTRUCTURES LTD 534690 LAKSHMI VILAS BANK LTD. 0.95 509631 HEG LTD 531522 RASOYA PROTEIBO LTD 0.70 524051 POLYPLEX CORP. LTD. 502420 ORIENT PAPER & INDUSTRIES LTD. 0.55 532481 NOIDA TOLL BRIDGE CO. LTD. 512105 SHREE NATH COMMERCIAL & 0.85 FINANCE LTD 509550 GAMMON INDIA LTD 512355 ANUKARAN COMMERCIAL 0.90 ENTERPRISES LT 512463 SHREE GLOBAL TRADEFIN LTD 530557 NCL RESEARCH & FINANCIAL 0.80 SERVICES LTD 513250 JYOTI STRUCTURES LTD 500027 ATUL LTD. 0.50 526853 BILCARE LTD. 523523 RAINBOW PAPERS LTD 0.65 514304 S KUMARS NATIONWIDE LTD 500241 KIRLOSKAR BROTHERS 0.40 505700 ELECON ENGINEERING CO. LTD. 533573 ALEMBIC PHARMACEUTICALS LTD 0.30 532475 APTECH LTD 534597 INDIABULLS INFRASTRUCTURE AND 0.60 POWER LTD. 500413 THOMAS COOK (INDIA) LTD 526797 GREENPLY INDUSTRIES LTD. 0.45 532793 SHREE ASHTAVINAYAK CINE 511676 GIC HOUSING FINANCE LTD 0.60 VISION LTD. 533292 A2Z MAINTENANCE AND 532689 PVR LTD 0.35 ENGINEERING SERVICES LTD 532786 GOL OFFSHORE LTD. 532929 BRIGADE ENTERPRISES LTD 0.45 522175 SHIV-VANI OIL & GAS 507205 TILAKNAGAR INDUSTRIES LTD 0.45 EXPLORATION SERVICES LTD 506074 ARSHIYA INTERNATIONAL LTD 532331 AJANTA PHARMA LTD 0.30 503699 GEODESIC LTD 534369 TRIBHOVANDAS BHIMJI ZAVERI LTD 0.25 532883 ZYLOG SYSTEMS LTD 533412 AANJANEYA LIFECARE LTD 0.50 500160 GTL LTD 532526 DISHMAN PHARMACEUTICALS & 0.40 CHEMICALS LTD 526015 KEMROCK INDUSTRIES & 533189 GOENKA DIAMOND AND JEWELS 0.30 EXPORTS LTD LTD 532691 TULIP TELECOM LTD 501425 BOMBAY BURMAH TRADING CORP 0.30 532672 GLODYNE TECHNOSERVE LTD. 532924 KOLTE-PATIL DEVELOPERS LTD 0.30 3. S&P BSE BANKEX Index: Exclusions: Inclusions: Code Name Code Name FFF 500116 IDBI Bank Ltd. NO INCLUSION 4. S&P BSE TECK Index: Exclusions: Inclusions: Code Name Code Name FFF HEXAWARE TECHNOLOGIES 532129 532819 MINDTREE LIMITED 0.85 LTD. 532691 TULIP TELCOM LTD 534816 BHARTI INFRATEL LIMITED 0.15 5. S&P BSE AUTO Index: Exclusions: Inclusions: Code Name Code Name FFF 500493 BHARAT FORGE LTD 517334 MOTHERSON SUMI SYSTEMS LTD 0.35 -- -- 500290 M.R.F. LTD 0.60 6. S&P BSE CAPITAL GOODS: Exclusions Inclusions Code Name Code Name FFF 522275 ALSTOM T&D INDIA 533177 IL&FS TRANSPORTATION NETWORKS 0.30 LTD LIMITED 532309 ALSTOM INDIA LTD 513375 CARBORUNDUM UNIVERSAL LTD 0.60 500048 BEML LTD -- -- -- 522205 PRAJ INDUSTRIES LTD. -- -- -- 7. S&P BSE CONSUMER DURABLES: Exclusions Inclusions Code Name Code Name FFF 517385 SYMPHONY LIMITED 534809 PC JEWELLER LIMITED 0.30 8. S&P BSE FMCG: Exclusions Inclusions Code Name Code Name FFF -- -- 500676 GLAXOSMITHKLINE CONSUMER HEALTHCARE LTD. 0.30 9. S&P BSE IT: Exclusions Inclusions Code Name Code Name FFF 526299 MPHASIS LIMITED 532819 MINDTREE LIMITED 0.85 10. S&P BSE METAL: Exclusions Inclusions Code Name Code Name FFF 500055 BHUSHAN STEEL LIMITED -- -- -- 11. S&P BSE REALTY: Exclusions Inclusions Code Name Code Name FFF 532780 PARSVNATH DEVELOPERS LTD. 533160 D B REALTY LIMITED 0.40 -- -- 512179 SUNTECK REALTY LTD 0.30 -- -- 503031 PENINSULA LAND LIMITED 0.45 12. S&P BSE POWER: Exclusions: Inclusions: Code Name Code Name FFF -- -- 532524 PTC INDIA LTD 0.85 JAIPRAKASH POWER VENTURES -- -- 532627 LIMITED 0.25 Please note that post Index review, there are no changes in the following indices - S&P BSE SENSEX, S&P BSE 100 Index, S&P BSE OIL & GAS, S&P BSE PSU, S&P BSE HEALTHCARE, S&P BSE CARBONEX and S&P BSE GREENEX. Change in constituents is made on the basis of guidelines governing inclusion and exclusion of companies from S&P BSE Indices. Detailed stock selection criteria for above mentioned indices are available at www.bseindia.com For any information / clarification, you may contact Index Services on +91 22 2272 8399 / 8440 or you can also write us at [email protected] Ketan P. Mehta - 98209 42920 Marketing Communications [email protected] May 24, 2013 .
Load more

Recommended publications
  • SANJEEVAK 1586083 01/08/2007 MANOJ ANANT JOSHI Trading As ;AKSHAY PHARMA REMEDIES KAVRANA HOUSE, OPP
    Trade Marks Journal No: 1836 , 12/02/2018 Class 5 SANJEEVAK 1586083 01/08/2007 MANOJ ANANT JOSHI trading as ;AKSHAY PHARMA REMEDIES KAVRANA HOUSE, OPP. COTTON GREEN RLY. STN. MUMBAI-400033. MANUFACTURE & MERCHANT INDIAN NATIONAL Used Since :31/01/2001 MUMBAI MEDICINAL PREPARATIONS. 537 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 SEPTIGARD 1741718 08/10/2008 INDERJIT SINGH trading as ;INDERJIT SINGH B-104 , SWASTHYA SINGH , NEW DELHI -92 MERCHANTS & MANUFACTUERERS Address for service in India/Agents address: MAHTTA & CO. 43 - B/3, MAHTTA HOUSE,UDHAM SINGH NAGAR, LUDHIANA - 141 001, (PUNJAB). Proposed to be Used DELHI MEDICINAL & PHARMACEUTICAL PREPARATIONS. 538 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 FAIR & BEAUTY 1803779 08/04/2009 GALPHA LABORATORIES LIMITED 221, Kanakia Zillion, E Wing Bandra Kurla Complex Annex LBS Marg & CST Road Junction Kurla West MUMBAI 400070 MANUFACTURERS AND MERCHANTS INDIAN NATIONAL Used Since :15/11/2007 MUMBAI PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES 539 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 O-BAMA 1815900 08/05/2009 KREMOINT PHARMA PVT. LTD. 151/5, SHRI KRISHNA DARSHAN, GARODIA NAGAR, GHATKOPAR (E), BOMBAY-400 077. MANUFACTURERS AND MERCHANTS. A CORPORATE ENTITY INCORPORATED IN INDIA UNDER THE COMPANIES ACT 1956. Address for service in India/Attorney address: KRISLAW CONSULTANTS BUILDING NO.4, C/104, SHANKESHWAR PALMS, BEHIND MODEL SCHOOL, KUMBHARKHANPADA, SUBHASH ROAD, DOMBIVILI(W) 421202 Used Since :02/05/2009 MUMBAI PHARMACETICAL AND MEDICINAL PREPARATIONS. 540 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 AYUSHAKTI D-VYRO 1815928 08/05/2009 SMITA NARAM BUNGALOW NO.31, NEXT TO M.
    [Show full text]
  • Consumer Goods Recovery in Discretionary and Urban Sales Led to Better Q3 Sector Update
    Consumer Goods Recovery in discretionary and urban sales led to better Q3 Sector Update Consumer goods companies’ Q3 performance was driven by sales recovery of Q3FY2021 Results Review discretionary categories (such as value-added hair oil and personal care products), sustained higher demand for healthcare and hygiene products, better traction to Sector: Consumer Goods new launches, and higher demand in rural markets coupled with improving demand in urban markets. General trade continues to grow strongly, e-commerce mix to Sector View: Positive overall revenue is improving due to higher sales and modern trade channel has witnessed sequential improvement due to recovery in urban sales. Most consumer goods companies under our coverage registered organic revenue growth of 6%-16%, driven by domestic volume growth of 7%-18% in Q3. Paint companies, including Asian Paints, registered strong volume growth of 30%, led by sustained high demand in tier III/IV towns and improving demand in metros and top cities due to receding scare of virus and improving construction and real estate activities. Overall, Sharekhan’s consumer goods universe registered revenue growth of ~14% in Q3FY2021, better than 9.1% growth achieved in Q2FY2021. Significant increase Our coverage universe in prices of palm oil, copra, other edible oils, and raw tea/coffee resulted in gross Companies CMP Reco. PT margin decline for companies such as HUL, Godrej Consumer Products (GCPL), (Rs) (Rs) Marico, and Tata Consumer Products (TCPL). However, lower ad spends and cost- Asian Paints 2,389 Buy 3,000 saving initiatives arrested the sharp decline of 80-100 bps in operating profit margins (OPM) for some companies.
    [Show full text]
  • Emami Companyname
    RESULT UPDATE EMAMI Health and rural focus to bear fruit India Equity Research| Consumer Goods COMPANYNAME Emami’s consolidated Q1FY21 revenue (down 25.8% YoY), EBITDA (down EDELWEISS 4D RATINGS 8.3% YoY) and PAT (up 1.2% YoY) were better than our estimates. The Absolute Rating BUY lockdown affected performance in April and May, but June (domestic Rating Relative to Sector Performer business up 8% YoY) turned out to be well. The recovery has sustained Risk Rating Relative to Sector High with double-digit growth in July. Soft mentha prices expanded gross Sector Relative to Market Underweight margin 231bps YoY; with mentha prices remaining benign, we expect gross margin expansion to sustain. A sharp cut in ad spends (down 749bps YoY) led to 487bps YoY EBITDA margin expansion. The lockdown MARKET DATA (R: EMAM.BO, B: HMN IN) affected international business (IB) as well overall sales dipped 18% YoY CMP : INR 257 Target Price : INR 296 (however up 7% YoY in June). Going ahead, with promoter-level pledging 52-week range (INR) : 358 / 131 concern alleviating in the wake of the recent Emami Cement sale, a slew Share in issue (mn) : 444.5 of launches in health & hygiene to capitalise on the topical upswing, and M cap (INR bn/USD mn) : 115 / 1,510 a higher rural contribution should hold the company in good stead. Avg. Daily Vol.BSE/NSE(‘000) : 958.1 Maintain ‘BUY’ with a TP of INR296. SHARE HOLDING PATTERN (%) Health & hygiene portfolio gains; discretionary portfolio suffers Current Q4FY20 Q3FY20 Key highlights: i) 43% of portfolio, which is aligned towards health & hygiene, grew Promoters * 53.9 52.7 52.7 29% YoY while the balance fell 44% YoY.
    [Show full text]
  • An Analysis of Corporate Social Responsibility Initiatives of Selected Manufacturing Companies in Karnataka
    IOSR Journal of Business and Management (IOSR-JBM) e-ISSN: 2278-487X, p-ISSN: 2319-7668 (April, 2017) PP 23-28 www.iosrjournals.org An Analysis of Corporate Social Responsibility Initiatives of Selected Manufacturing Companies in Karnataka Ramaprakasha. N1 & Dr.Y.Rajaram2 1 Faculty, Maharaja’s College, University of Mysore, Mysuru. 2 Professors, Ramaiah Institute of Management Studies, Bengaluru. Abstract: The enactment of The New Companies Act 2013 is a major milestone in corporate governance, which has resulted in a paradigm shift in business operations across India. Almost all major companies are practicing corporate social responsibility (CSR) and are contributing towards the development of society and environment within which they operate. In the present paper an attempt has been made to throw light on the prominent corporate social responsibility initiatives of the selected manufacturing companies in Karnataka, to determine the trend and orientation of corporate social responsibility and to examine whether there is significant difference in the orientation and implementation of corporate social responsibility initiatives among the selected manufacturing companies in Karnataka. Key words: Corporate social responsibility, Karnataka, Manufacturing companies. I. Introduction Corporate Social Responsibility (CSR) has developed as an important area of management after the enactment of The New Companies Act-2013. CSR is defined as the obligations of a company towards the society and environment within which it operates. CSR was previously a voluntary exercise which were practiced only by a few reputed companies but The New Companies Act which came into force from 01 April, 2014 in India made corporate social responsibility mandatory for companies operating in India having a net profit of Rs 5 crores or above or a net worth of Rs 500 crores or above or a total turnover of Rs 1000 crores or above during any financial year.
    [Show full text]
  • The Australia-India Economic Relationship Mark Thirlwell Chief Economist Australia and India: a Developing Bilateral Relationship Top Ten Trading Partners, 2014-15
    Room to grow: The Australia-India economic relationship Mark Thirlwell Chief Economist Australia and India: A developing bilateral relationship Top ten trading partners, 2014-15 Australia's two-way trade with India A$ billions Per cent of all goods and services trade Top ten trading partners goods and services, 2014-15 25 5 A$ bn Share (%) 1 China 149.8 22.7 Value (LHS) 2 Japan 67.7 10.3 20 4 3 United States 64.6 9.8 Share of total (RHS) 4 Korea 34.8 5.3 5 Singapore 28.4 4.3 15 3 6 New Zealand 23.7 3.6 7 United Kingdom 21.1 3.2 8 Thailand 19.9 3.0 10 2 9 Malaysia 19.6 3.0 10 India 18.0 2.7 Subtotal 447.5 67.8 5 1 Total all countries 660.0 100.0 ASEAN 98.6 14.9 0 0 EU 83.1 12.6 Source: DFAT annual direction of trade data Australia Unlimited 3 Balance of trade and exchange rate Australia's trade surplus with India Australia-India bilateral exchange rate A$ billions A$1=INR, end of month* 20 Goods Services 60 55 15 50 10 45 5 40 0 35 Source: DFAT annual direction of trade data Source: RBA. * For February 2016, value is for close on 23 February, not month end Australia Unlimited 4 Top ten export markets 2014-15: Goods vs Services Top ten export markets for goods 2014-15 Top ten export markets for services 2014-15 A$ bn Share (%) A$ bn Share (%) 1 China 81.5 31.8 1 China 8.8 14.1 2 Japan 44.5 17.4 2 United States 7.1 11.3 3 Republic of Korea 18.8 7.4 3 United Kingdom 4.9 7.8 4 United States 13.4 5.2 4 New Zealand 4.0 6.4 5 India 9.8 3.8 5 Singapore 3.8 6.0 6 New Zealand 8.3 3.2 6 India 2.9 4.6 7 Singapore 8.3 3.2 7 Hong Kong SAR 2.1 3.4 8 Taiwan
    [Show full text]
  • HSBC Saudi Arabia Limited
    HSBC Saudi Arabia Limited HSBC China & India Equity Freestyle Fund - IAF Fund Details Monthly Factsheet Fund Manager HSBC Saudi Arabia Ltd. as of 31 January 2015 Inception Date 12 December 2005 Profile Inception Price USD 10 To provide capital appreciation through investing in a well-diversified portfolio comprising of shares in Indian and Chinese companies over a long period of five years and above . Fund Type Open ended Top Holdings Investment Policy Freestyle Management Stock Weight % Base Currency US Dollar of the Fund Tencent Holdings Ltd. 10 Baidu Inc. Sponsored ADR 9 Risk/Return Profile High Infosys Ltd. 8 Bloomberg Code SABCHIN AB Wipro Ltd. 7 Emami Ltd. 5 Zawya Code HSBCIEF.MF Oil & Natural Gas Corp. Ltd. 4 Fund Size (USD) 44 Million HCL Technologies Ltd. 4 Minimum Initial USD 2,000 Maruti Suzuki India Ltd. 4 Investment Cognizant Tech Solutions 4 Glenmark Pharmaceuticals Ltd. 4 Minimum Additional USD 1,000 Investment Fund Composition Valuation Day Monday & Thursday Cut off Time Before close of business; On Sunday for Monday valuation, and on Wednesday for Thursday valuation. Redeemed Funds Four business days Payment after valuation day Annual Management Fee 2% Subscription Fee Up to 2% Contact Details HSBC Saudi Arabia Limited Local Investors Toll Free Number 800 124 1212 International Investors Tel +966 1 299 2313 / +966 1 299 2314 Website www.hsbcsaudi.com Email: [email protected] Issued by HSBC Saudi Arabia Limited Authorized and regulated by Capital Market Authority License No. 05008-37 Please note that the above figures refer to past performance and that past performance is not a reliable indicator of future results.
    [Show full text]
  • Ajanta Pharma Limited
    AJANTA PHARMA LIMITED CIN : L24230MH1979PLC022059 Registered & Corporate Office: ‘Ajanta House’, 98 Govt Industrial Area, Charkop, Kandivli (West), Mumbai - 400 067, Maharashtra, India Tel.: +91 22 6606 1000, Fax: +91 22 6606 1200 | E-mail: [email protected] | Website: www.ajantapharma.com POST BUYBACK PUBLIC ANNOUNCEMENT FOR THE ATTENTION OF EQUITY SHAREHOLDERS/ BENEFICIAL OWNERS OF EQUITY SHARES OF AJANTA PHARMA LIMITED This public announcement (the “Post Buyback Public Announcement”) is being made pursuant to the provisions of Regulation 24(vi) of the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, for the time being in force including any statutory modifications and amendments from time to time (the “Buyback Regulations”). This Post Buyback Public Announcement should be read in conjunction with the Public Announcement dated November 4, 2020 which was published on November 5, 2020 (the “Public Announcement”) and the letter of offer dated November 25, 2020 (the “Letter of Offer”) issued in connection with the Buyback. The terms used but not defined in this Post Buyback Public Announcement shall have the same meanings as assigned in the Public Announcement and the Letter of Offer. 1. THE BUYBACK 1.1 Ajanta Pharma Limited (the “Company”) had announced the Buyback of not exceeding 7,35,000 (Seven Lakh Thirty Five Thousand) fully paid-up equity shares of face value of ₹2 each (“Equity Shares”) from all the existing shareholders / beneficial owners of Equity Shares as on the record date (i.e. Friday, November 13, 2020), on a proportionate basis, through the “Tender Offer” process at a price of ₹1,850/- (Rupees One Thousand Eight Hundred and Fifty Only) per Equity Share payable in cash for an aggregate consideration not exceeding ₹ 135,97,50,000 (Rupees One Hundred Thirty Five Crores Ninety Seven Lakhs and Fifty Thousand only) excluding the Transaction Costs (“Buyback Offer Size”).
    [Show full text]
  • Inner 25 India Pharma & Healthcare Fund
    Modera erate tely Mod High to e H w at ig o er h L d o M V e r y w H Tata India Pharma & Healthcare Fund o i L g (An open ended equity scheme investing in Pharma and Healthcare Services Sector) h Riskometer Investors understand that their principal As on 30th June 2021 PORTFOLIO will be at Very High Risk INVESTMENT STYLE Company name No. of Market Value % of Company name No. of Market Value % of Primarily focuses on investment in at least 80% of its net Shares Rs. Lakhs Assets Shares Rs. Lakhs Assets assets in equity/equity related instruments of the companies in the Pharma & Healthcare sectors in India. Equity & Equity Related Total 55184.24 97.88 Glenmark Pharmaceuticals Ltd. 167000 1089.76 1.93 INVESTMENT OBJECTIVE Healthcare Services Sanofi India Ltd. 13000 997.39 1.77 The investment objective of the scheme is to seek long Apollo Hospitals Enterprise Ltd. 70500 2551.99 4.53 Gland Pharma Ltd. 19662 673.29 1.19 term capital appreciation by investing atleast 80% of its Fortis Healthcare Ltd. 795000 1935.03 3.43 Laurus Labs Ltd. 90000 619.79 1.10 net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in Syngene International Ltd. 265000 1545.75 2.74 India.However, there is no assurance or guarantee that the investment objective of the Scheme will be Narayana Hrudayalaya Ltd. 301420 1483.74 2.63 Other Equities^ 1186.14 2.10 achieved.The Scheme does not assure or guarantee any Metropolis Healthcare Ltd.
    [Show full text]
  • MF 35 Fund One Pager
    BR“BuyS RightT : BSit TightR” ST BRSnowT Bin fourRS differentTBRS colorsTBRS BRSTBRSTBRSTBR Motilal Oswal MOSt Focused Invests in enduring B25 RFund STBRSTBwRealth creaStors T Motilal Oswal MOSt Focused Invests in emerging BMidcapR 30 Fund TBRwealth creators T BRSTBSRSTBRSTBSRS Motilal Oswal MOSt Focused Invests in emerging and BMulticapRS 35 FundT BRSTBRenduringST wealthB creatorRs Lock in fund that invests Motilal Oswal MOSt Focused in wealth creators BLongR Term SFund TBRSTBplusR Saves TSax T BR TBR T BRSTBSRSTBRSTBSRS Focused Low Churn QGLP No load BRSTBPortfolioRSTBPortfolioRSTStocksBR BRSInvesTt nowB to addR colorSs Tto yourB porRolioST BRSCall:T 1800-200-6626B | SMS:R FOCUSS to 575753T BRSTBRS Website: www.motilaloswalmf.com Our Investment Philosophy The recommended way to create Wealth from equity- 'Buy Right : Sit Tight' At Molal Oswal Asset Management Company (MOAMC), our investment philosophy and invesng style is centered on 'Buy Right: Sit Tight‘ principal. ‘Buy Right' means buying quality companies at a reasonable price and 'Sit Tight' means staying invested in them for a longer me to realise the full growth potenal of the stocks. Buy Right Stock Characteristics Sit Tight Approach QGLP ‘Q’uality denotes quality of the business and Buy and Hold: We are strictly buy and hold management investors and believe that picking the right ‘G’rowth denotes growth in earnings and business needs skill and holding onto these sustained RoE businesses to enable our investors to benefit from the entire growth cycle needs even more ‘L’ongevity denotes longevity of the skill. competitive advantage or economic moat of the business Focus: Our portfolios are high conviction portfolios with 20 to 25 stocks being our ideal ‘P’rice denotes our approach of buying a good n u m b e r.
    [Show full text]
  • CARE Ratings Ltd
    CARE/HO/RL/2020-21/2749 Mr. Arvind Agrawal Chief Financial Officer Ajanta Pharma Limited Ajanta House, Charkop, Kandivali (W), Mumbai-400067 October 1, 2020 Confidential Dear Sir, Credit rating for bank facilities On the basis of recent developments including operational and financial performance of your company for FY20 (audited) and Q1FY21 (provisional), our Rating Committee has reviewed the following ratings: Facilities Amount Rating1 Rating (Rs. crore) Action Long-term/Short-term Bank 55.00 CARE AA; Stable/CARE A1+ Facilities (reduced from 87.50) (Double A; Outlook: Stable/A Reaffirmed One Plus) Total 55.00 (Rs. Fifty Five crore only) 2. Refer Annexure 1 for details of rated facilities. 3. The rationale for the rating will be communicated to you separately. A write-up (press release) on the above rating is proposed to be issued to the press shortly, a draft of which is enclosed for your perusal as Annexure-2. We request you to peruse the annexed document and offer your comments if any. We are doing this as a matter of courtesy to our clients and with a view to ensure that no factual inaccuracies have inadvertently crept in. Kindly revert as early as possible. In any case, if we do not hear from you by October 5, 2020 we will proceed on the basis that you have no any comments to offer. 4. CARE reserves the right to undertake a surveillance/review of the rating from time to time, based on circumstances warranting such review, subject to at least one such review/surveillance every year. 5.
    [Show full text]
  • Emami (HMN IN)
    Emami (HMN IN) Rating: BUY | CMP: Rs444 | TP: Rs526 December 2, 2020 Enters virtuous cycle of Seasonality; BUY Company Update Quick Pointers: Change in Estimates | ☑ Target | Reco . Early onset of winter has boosted demand for Winter care products Change in Estimates . Strong rural demand and Low base (3Q growth of 3.3% in past 5 years) augur Current Previous well for demand, base in 4Q21 and 1Q22 will be -19.7% and -25.8% FY22E FY23E FY22E FY23E Rating BUY BUY Target Price 526 450 . Most power brands are in good shape except F&H, we are cautious on new Sales (Rs. m) 31,293 34,585 31,293 34,585 launches despite encouraging initial response % Chng. - - EBITDA (Rs. m) 9,299 9,988 9,299 9,988 % Chng. - - We are upgrading target price of Emami to Rs526 (Rs450 earlier) as we EPS (Rs.) 16.7 18.8 16.7 18.8 % Chng. - - increase PE multiple from 26 to 28x (last 5-year average 38.6x, 25% discount to coverage universe) and rollover valuations to FY23. We believe Emami has Key Financials - Standalone hit a sweet spot for growth led by 1) Strong rural demand as it is 55% of sales Y/e Mar FY20 FY21E FY22E FY23E for Emami 2) strong demand for winter care products on early onset of winter Sales (Rs. m) 26,549 27,780 31,293 34,585 3) low base for 3Q ( 5 year sales growth of 3.3%, 19.7% and 25.8% decline in EBITDA (Rs. m) 6,905 8,594 9,299 9,988 4Q and 1Q) 4) Kesh king has gained traction and is gaining share in premium Margin (%) 26.0 30.9 29.7 28.9 PAT (Rs.
    [Show full text]
  • PUBLIC ANNOUNCEMENT for the ATTENTION of EQUITY SHAREHOLDERS/ BENEFICIAL OWNERS of As Partner of Ganga Exports, Where the Partner’S Share Being 37.5%
    ii. Shareholding of directors of the Promoters and Promoter Group entity (i.e. Gabs Investment Private Limited ii. the amount of permissible capital payment (including premium) as stated in Annexure A for the proposed (“GIPL”)) in the Company: buy-back of equity shares has been properly determined considering the audited standalone financial statements and audited consolidated financial statements in accordance with Section 68(2) of the Act; and Sr. Designation No. of Equity Shares held Percentage (%) of issued Name iii. the Board of Directors of the Company in their meeting dated 3 November 2020, have formed the opinion No. in GIPL in the Company Equity Share capital as specified in clause (x) of Schedule I to the SEBI Buy-back Regulations on reasonable grounds and 1. Yogesh Agrawal Director 1,35,36,523(1) 15.51 that the Company will not, having regard to its state of affairs, be rendered insolvent within a period AJANTA PHARMA LIMITED 2. Rajesh Agrawal Director 1,35,36,522(2) 15.51 of one year from that date. CIN : L24230MH1979PLC022059 3. Ravi Agrawal Director 1,33,32,906(3) 15.28 Auditors’ Responsibility (Continued) Registered & Corporate Office: ‘Ajanta House’, 98 Govt Industrial Area, Charkop, 4. Aayush Agrawal Director 1,25,60,389(4) 14.39 5. The audited standalone financial statements and audited consolidated financial statements referred to in Kandivli (West), Mumbai - 400 067, Maharashtra, India Total 5,29,66,340 60.69 paragraph 5 above, which we have considered for the purpose of this report, have been audited by us, on Tel.: +91 22 6606 1000, Fax: +91 22 6606 1200 | E-mail: [email protected] which we have issued an unmodified audit opinion vide our reports dated 20 May 2020.
    [Show full text]